COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies
© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd..
COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis. Among these, 62 (26·2%) had myeloid, 121 (51·1%) lymphoid and 54 (22·8%) plasma cell neoplasms. Overall, 69% of patients (164 of 237) had detectable IgG SARS-CoV-2 serum antibodies. Serologically negative patients (31%, 73 of 237) were evenly distributed across patients with myeloid, lymphoid and plasma cell neoplasms. In the multivariable logistic regression, chemoimmunotherapy [odds ratio (OR), 3·42; 95% confidence interval (CI), 1·04-11·21; P = 0·04] was associated with a lower rate of seroconversion. This effect did not decline after 180 days from treatment withdrawal (OR, 0·35; 95% CI: 0·11-1·13; P = 0·08). This study demonstrates a low rate of seroconversion in HM patients and indicates that treatment-mediated immune dysfunction is the main driver. As a consequence, we expect a low rate of seroconversion after vaccination and thus we suggest testing the efficacy of seroconversion in HM patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:195 |
|---|---|
| Enthalten in: |
British journal of haematology - 195(2021), 3 vom: 16. Nov., Seite 371-377 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Passamonti, Francesco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 09.11.2021 Date Revised 05.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.17704 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328180971 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328180971 | ||
| 003 | DE-627 | ||
| 005 | 20231225202414.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.17704 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1093.xml |
| 035 | |a (DE-627)NLM328180971 | ||
| 035 | |a (NLM)34272724 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Passamonti, Francesco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.11.2021 | ||
| 500 | |a Date Revised 05.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis. Among these, 62 (26·2%) had myeloid, 121 (51·1%) lymphoid and 54 (22·8%) plasma cell neoplasms. Overall, 69% of patients (164 of 237) had detectable IgG SARS-CoV-2 serum antibodies. Serologically negative patients (31%, 73 of 237) were evenly distributed across patients with myeloid, lymphoid and plasma cell neoplasms. In the multivariable logistic regression, chemoimmunotherapy [odds ratio (OR), 3·42; 95% confidence interval (CI), 1·04-11·21; P = 0·04] was associated with a lower rate of seroconversion. This effect did not decline after 180 days from treatment withdrawal (OR, 0·35; 95% CI: 0·11-1·13; P = 0·08). This study demonstrates a low rate of seroconversion in HM patients and indicates that treatment-mediated immune dysfunction is the main driver. As a consequence, we expect a low rate of seroconversion after vaccination and thus we suggest testing the efficacy of seroconversion in HM patients | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a leukemia | |
| 650 | 4 | |a lymphoma | |
| 650 | 4 | |a myeloma | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Romano, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Salvini, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Merli, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Porta, Matteo G Della |e verfasserin |4 aut | |
| 700 | 1 | |a Bruna, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Coviello, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Romano, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Cairoli, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Lemoli, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Farina, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Venditti, Adriano |e verfasserin |4 aut | |
| 700 | 1 | |a Busca, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Ladetto, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Massaia, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Arcaini, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Tafuri, Agostino |e verfasserin |4 aut | |
| 700 | 1 | |a Marchesi, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Fracchiolla, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Bocchia, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Armiento, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Candoni, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Krampera, Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Luppi, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Cardinali, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Galimberti, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Cattaneo, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a La Barbera, Elettra Ortu |e verfasserin |4 aut | |
| 700 | 1 | |a Mina, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Lanza, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Visani, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Musto, Pellegrino |e verfasserin |4 aut | |
| 700 | 1 | |a Petrucci, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Zaja, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Grossi, Paolo A |e verfasserin |4 aut | |
| 700 | 1 | |a Bertù, Lorenza |e verfasserin |4 aut | |
| 700 | 1 | |a Pagano, Livio |e verfasserin |4 aut | |
| 700 | 1 | |a Corradini, Paolo |e verfasserin |4 aut | |
| 700 | 0 | |a ITA-HEMA-COV Investigators* |e verfasserin |4 aut | |
| 700 | 1 | |a Derenzini, Enrico |e investigator |4 oth | |
| 700 | 1 | |a Marchetti, Monia |e investigator |4 oth | |
| 700 | 1 | |a Scattolin, Anna M |e investigator |4 oth | |
| 700 | 1 | |a Corso, Alessandro |e investigator |4 oth | |
| 700 | 1 | |a Tosi, Patrizia |e investigator |4 oth | |
| 700 | 1 | |a Gherlinzoni, Filippo |e investigator |4 oth | |
| 700 | 1 | |a Passerini, Carlo Gambacorti |e investigator |4 oth | |
| 700 | 1 | |a Cavo, Michele |e investigator |4 oth | |
| 700 | 1 | |a Fava, Carmen |e investigator |4 oth | |
| 700 | 1 | |a Turrini, Mauro |e investigator |4 oth | |
| 700 | 1 | |a Visco, Carlo |e investigator |4 oth | |
| 700 | 1 | |a Zappasodi, Patrizia |e investigator |4 oth | |
| 700 | 1 | |a Merli, Michele |e investigator |4 oth | |
| 700 | 1 | |a Mora, Barbara |e investigator |4 oth | |
| 700 | 1 | |a Vannucchi, Alessandro M |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 195(2021), 3 vom: 16. Nov., Seite 371-377 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:195 |g year:2021 |g number:3 |g day:16 |g month:11 |g pages:371-377 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.17704 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 195 |j 2021 |e 3 |b 16 |c 11 |h 371-377 | ||